摘要
目的探讨对高度近视黄斑脉络膜新生血管患者采用雷珠单抗玻璃体注射方法进行治疗后对不同时期光学相干断层扫描(OCT)产生的影响。方法将该院2017年6月-2020年3月收治的60例高度近视黄斑脉络膜新生血管患者作为研究对象;临床选择0.5 mg(0.05 mL)雷珠单抗对患者实施玻璃体腔注射。完成注射后不同时间段对患者展开随访操作;于前2次随访期间,准备相同剂量雷珠单抗对患者实施玻璃体腔注射;随访期间就患者OCT检查黄斑中心凹视网膜厚度(CFT)以及最佳矫正视力等展开对应检查,就不同时间段眼底OCT变化展开对比。结果采用雷珠单抗对患者注射后,同注射前比较,视力均获得显著提高,术后1个月、2个月、3个月以及6个月分别表现为(1.44±2.12)行、(1.54±2.49)行、(1.88±2.30)行以及(1.68±2.59)行;采用雷珠单抗对患者注射后通过OCT发现,手术前、手术后1个月、手术后2个月、手术后3个月以及手术后6个月CFT分别为(354.59±25.35)、(301.23±22.95)、(290.19±18.36)、(272.85±31.27)、(262.55±26.83)μm,同手术前CFT水平比较,手术后不同时间段CFT水平均呈现出显著减小,差异有统计学意义(t=12.087、15.937、15.729、19.315,P<0.05)。结论雷珠单抗玻璃体注射方法有效运用,可使高度近视黄斑脉络膜新生血管患者视力水平获得显著提升,并且使不同时期OCT水平获得显著降低,最终实现高度近视黄斑脉络膜新生血管患者有效预后。
Objective To investigate the effect of vitreous injection of ranibizumab on OCT(optical coherence tomography)in patients with high myopia macular choroidal neovascularization at different periods.Methods Sixty patients with high myopia macular choroidal neovascularization admitted to the hospital from June 2017 to March 2020 were selected as experimental subjects;0.5 mg(0.05 mL)ranibizumab was selected clinically for intravitreal injection of patients,complete follow-up at different time periods after the injection;during the first 2 follow-ups,prepare the same dose of ranibizumab for intravitreal injection of the patients;during the follow-up,check the CFT(macular foveal retinal thickness)and the best correction during the follow-up.Visual acuity and other corresponding examinations were carried out to compare the changes in fundus OCT at different time periods.Results After the injection of ranibizumab,the visual acuity of the patient was significantly improved compared with before the injection.1,2,3 and 6 months after the operation,the visual acuity was(1.44±2.12)line,(1.54±2.49)line,(1.88±2.30)line and(1.68±2.59)line;after the injection of ranibizumab to the patient,it was found by OCT,before the operation,1 month after the operation,2 months after the operation,3 months after the operation and 6 months after surgery CFT were(354.59±25.35)μm,(301.23±22.95)μm,(290.19±18.36)μm,(272.85±31.27)μm,and(262.55±26.83)μm respectively;compared with the level of CFT before surgery,CFT levels in different time periods after surgery showed a significant decrease,the difference was statistically significant(t=12.087,15.937,15.729,19.315,P<0.05).Conclusion The effective use of ranibizumab intravitreal injection can significantly improve the visual acuity of patients with high myopia macular choroidal neovascularization,and significantly reduce OCT levels in different periods,and finally achieve an effective prognosis for patients with high myopic macular choroidal neovascularization.
作者
陶建军
TAO Jianjun(Department of Ophthalmology,Changshu Second People's Hospital,Changshu,Jiangsu Province,215500 China)
出处
《系统医学》
2021年第20期89-91,共3页
Systems Medicine
